Gilead signs $3 billion licensing deal for Sangamo's gene-editing platform

(Reuters) - Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.